---
document_datetime: 2025-12-29 11:06:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/wegovy.html
document_name: wegovy.html
version: success
processing_time: 0.1215631
conversion_datetime: 2025-12-31 03:28:42.73491
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Wegovy

[RSS](/en/individual-human-medicine.xml/67518)

##### Authorised

This medicine is authorised for use in the European Union

semaglutide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Wegovy](#news-on)
- [Related documents](#related-documents-68984)
- [More information on Wegovy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Wegovy is used together with diet and physical activity to help people to lose weight and keep their weight under control. It is used in adults who have: • a BMI of 30 kg/m² or greater (obesity) or • a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) who have weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called 'obstructive sleep apnoea' or a history of heart attack, stroke or blood vessel problems). It is also used in adolescents from 12 years of age whose BMI is at or above the 95th percentile for their age and gender (obesity) and who weigh more than 60 kg. BMI (body mass index) is a measure of your weight in relation to your height. A BMI at the 95th percentile means that it is greater than that of 95% of people of the same age and gender. Wegovy contains the active substance semaglutide.

Expand section

Collapse section

## How is Wegovy used?

Wegovy is available as pre-filled pens containing a solution for injection. It is injected once a week under the skin in the belly, thigh or upper arm.

## How does Wegovy work?

The active substance in Wegovy, semaglutide, is a 'GLP-1 receptor agonist'. It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person's feelings of fullness, while reducing their food intake, hunger and cravings.

## What benefits of Wegovy have been shown in studies?

Studies have shown that Wegovy is effective in helping people lose weight, with a significant proportion of them achieving at least a 5% weight reduction.

## What are the risks associated with Wegovy?

The most common side effects with Wegovy (which may affect more than 1 in 10 people) are headache, nausea (feeling sick), vomiting, diarrhoea, constipations and abdominal (belly) pain. For the full list of side effects and restrictions of Wegovy, see the package leaflet.

## Why is Wegovy authorised in the EU?

Obesity can lead to severe health problems and many people with obesity experience difficulty trying to lose weight. Wegovy is effective at reducing weight in adults with obesity or who are overweight with a weight-related health problem. It is also effective in adolescents with obesity, but there were not enough data on overweight adolescents. The medicine's side effects are considered manageable. However, to prevent unnecessary long-term treatment, treatment should be stopped if adolescents do not achieve a weight loss of at least 5% within 12 weeks on the maximum dose or maximum tolerated dose. The European Medicines Agency therefore decided that Wegovy's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Wegovy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Wegovy have been included in the summary of product characteristics and the package leaflet. As for all medicines, data on the use of Wegovy are continuously monitored. Suspected side effects reported with Wegovy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Wegovy

Wegovy received a marketing authorisation valid throughout the EU on 6 January 2022. Further information on Wegovy can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/wegovy This overview was last updated in 04-2023.

Wegovy : EPAR - Medicine Overview

Reference Number: EMA/162766/2023

English (EN) (117.86 KB - PDF)

**First published:** 10/03/2022

**Last updated:** 09/06/2023

[View](/en/documents/overview/wegovy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-532)

български (BG) (130.17 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/bg/documents/overview/wegovy-epar-medicine-overview_bg.pdf)

español (ES) (118.3 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/es/documents/overview/wegovy-epar-medicine-overview_es.pdf)

čeština (CS) (124.33 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/cs/documents/overview/wegovy-epar-medicine-overview_cs.pdf)

dansk (DA) (117.46 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/da/documents/overview/wegovy-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.42 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/de/documents/overview/wegovy-epar-medicine-overview_de.pdf)

eesti keel (ET) (117.2 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/et/documents/overview/wegovy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.19 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/el/documents/overview/wegovy-epar-medicine-overview_el.pdf)

français (FR) (121.05 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/fr/documents/overview/wegovy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (120.3 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/hr/documents/overview/wegovy-epar-medicine-overview_hr.pdf)

italiano (IT) (118.91 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/it/documents/overview/wegovy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (130.27 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/lv/documents/overview/wegovy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (119.46 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/lt/documents/overview/wegovy-epar-medicine-overview_lt.pdf)

magyar (HU) (121.37 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/hu/documents/overview/wegovy-epar-medicine-overview_hu.pdf)

Malti (MT) (124.57 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/mt/documents/overview/wegovy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.52 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/nl/documents/overview/wegovy-epar-medicine-overview_nl.pdf)

polski (PL) (121.26 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/pl/documents/overview/wegovy-epar-medicine-overview_pl.pdf)

português (PT) (117.94 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/pt/documents/overview/wegovy-epar-medicine-overview_pt.pdf)

română (RO) (120.99 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/ro/documents/overview/wegovy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (123.3 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/sk/documents/overview/wegovy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.47 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/sl/documents/overview/wegovy-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.12 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/fi/documents/overview/wegovy-epar-medicine-overview_fi.pdf)

svenska (SV) (116.35 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

09/06/2023

[View](/sv/documents/overview/wegovy-epar-medicine-overview_sv.pdf)

Wegovy : EPAR - Risk management plan summary

English (EN) (271.55 KB - PDF)

**First published:** 10/03/2022

**Last updated:** 09/06/2023

[View](/en/documents/rmp-summary/wegovy-epar-risk-management-plan-summary_en.pdf)

## Product information

Wegovy : EPAR - Product Information

English (EN) (1 MB - PDF)

**First published:** 10/03/2022

**Last updated:** 30/09/2025

[View](/en/documents/product-information/wegovy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-856)

български (BG) (1.14 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/bg/documents/product-information/wegovy-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/es/documents/product-information/wegovy-epar-product-information_es.pdf)

čeština (CS) (1.08 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/cs/documents/product-information/wegovy-epar-product-information_cs.pdf)

dansk (DA) (996.13 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/da/documents/product-information/wegovy-epar-product-information_da.pdf)

Deutsch (DE) (997 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/de/documents/product-information/wegovy-epar-product-information_de.pdf)

eesti keel (ET) (1.05 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/et/documents/product-information/wegovy-epar-product-information_et.pdf)

ελληνικά (EL) (1.21 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/el/documents/product-information/wegovy-epar-product-information_el.pdf)

français (FR) (1.1 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/fr/documents/product-information/wegovy-epar-product-information_fr.pdf)

hrvatski (HR) (1.07 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/hr/documents/product-information/wegovy-epar-product-information_hr.pdf)

íslenska (IS) (1003.81 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/is/documents/product-information/wegovy-epar-product-information_is.pdf)

italiano (IT) (1009.09 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/it/documents/product-information/wegovy-epar-product-information_it.pdf)

latviešu valoda (LV) (1.17 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/lv/documents/product-information/wegovy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.1 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/lt/documents/product-information/wegovy-epar-product-information_lt.pdf)

magyar (HU) (1.11 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/hu/documents/product-information/wegovy-epar-product-information_hu.pdf)

Malti (MT) (1.16 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/mt/documents/product-information/wegovy-epar-product-information_mt.pdf)

Nederlands (NL) (990.63 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/nl/documents/product-information/wegovy-epar-product-information_nl.pdf)

norsk (NO) (975.91 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/no/documents/product-information/wegovy-epar-product-information_no.pdf)

polski (PL) (1.11 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/pl/documents/product-information/wegovy-epar-product-information_pl.pdf)

português (PT) (1021.14 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/pt/documents/product-information/wegovy-epar-product-information_pt.pdf)

română (RO) (1.23 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/ro/documents/product-information/wegovy-epar-product-information_ro.pdf)

slovenčina (SK) (1.18 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/sk/documents/product-information/wegovy-epar-product-information_sk.pdf)

slovenščina (SL) (1.06 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/sl/documents/product-information/wegovy-epar-product-information_sl.pdf)

Suomi (FI) (1 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/fi/documents/product-information/wegovy-epar-product-information_fi.pdf)

svenska (SV) (1.06 MB - PDF)

**First published:**

10/03/2022

**Last updated:**

30/09/2025

[View](/sv/documents/product-information/wegovy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287437 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Wegovy : EPAR - All authorised presentations

English (EN) (31.84 KB - PDF)

**First published:** 10/03/2022

**Last updated:** 12/06/2024

[View](/en/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-312)

български (BG) (69.83 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/bg/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.08 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/es/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.64 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/cs/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.33 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/da/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.93 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/de/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.89 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/et/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.27 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/el/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_el.pdf)

français (FR) (31.42 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/fr/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.65 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/hr/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.92 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/is/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (30.27 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/it/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.28 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/lv/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.83 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/lt/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.94 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/hu/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (54.13 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/mt/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.17 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/nl/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.1 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/no/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_no.pdf)

polski (PL) (56.2 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/pl/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.02 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/pt/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.45 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/ro/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.74 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/sk/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.85 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/sl/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.79 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/fi/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (30.55 KB - PDF)

**First published:**

10/03/2022

**Last updated:**

12/06/2024

[View](/sv/documents/all-authorised-presentations/wegovy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Wegovy Active substance semaglutide International non-proprietary name (INN) or common name semaglutide Therapeutic area (MeSH)

- Obesity
- Overweight

Anatomical therapeutic chemical (ATC) code A10BJ06

### Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

### Therapeutic indication

Adults

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to &lt;30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

For trial results with respect to cardiovascular risk reduction and populations studied, see section 5.1.

Adolescents (≥12 years)

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with • obesity* and • body weight above 60 kg.

Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.

*Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1 in 4.1 of SmPC).

Table 1 BMI cut-off points for obesity (≥95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria)

## Authorisation details

EMA product number EMEA/H/C/005422

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Novo Nordisk A/S

Novo Alle 1

Opinion adopted 11/11/2021 Marketing authorisation issued 06/01/2022 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Wegovy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.64 KB - PDF)

**First published:** 30/09/2025

[View](/en/documents/procedural-steps-after/wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Wegovy : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (183.24 KB - PDF)

**First published:** 26/07/2022

**Last updated:** 30/09/2025

[View](/en/documents/procedural-steps-after/wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Wegovy-H-C-005422-II-0017 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMEA/400658/2024

English (EN) (3.02 MB - PDF)

**First published:** 06/09/2024

[View](/en/documents/variation-report/wegovy-h-c-005422-ii-0017-epar-assessment-report-variation_en.pdf)

Wegovy-H-C-005422-II-0009 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/141429/2023

English (EN) (2.62 MB - PDF)

**First published:** 30/01/2024

[View](/en/documents/variation-report/wegovy-h-c-005422-ii-0009-epar-assessment-report-variation_en.pdf)

Wegovy-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/193286/2023

English (EN) (105.37 KB - PDF)

**First published:** 09/06/2023

[View](/en/documents/scientific-conclusion/wegovy-h-c-psusa-00010671-202205-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of opinion for Wegovy (II-09)

Adopted

Reference Number: EMA/141466/2023

English (EN) (126.64 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-wegovy-ii-09_en.pdf)

## Initial marketing authorisation documents

Wegovy : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/112307/2022

English (EN) (5.59 MB - PDF)

**First published:** 10/03/2022

[View](/en/documents/assessment-report/wegovy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Wegovy

Adopted

Reference Number: EMA/CHMP/639299/2021

English (EN) (174.49 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-wegovy_en.pdf)

#### News on Wegovy

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-june-2025) 06/06/2025

[PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy](/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) 06/06/2025

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-january-2025) 17/01/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

#### Related documents

Questions and answers on the outcome of assessment to extend the use of Wegovy (semaglutide)

Reference Number: EMA/340123/2024

English (EN) (128.64 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/medicine-qa/questions-answers-outcome-assessment-extend-use-wegovy-semaglutide_en.pdf)

#### More information on Wegovy

- [EMEA-001441-PIP08-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001441-pip08-23)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)